Dear Editor

Isolated laryngeal amyloidosis is a rare cause of hoarseness. There are few reports regarding isolated laryngeal amyloidosis.\textsuperscript{1, 2} Literature review shows a potential role for hepatitis B virus (HBV) infection in occurrence of multiple myeloma.\textsuperscript{3}

A 66-year-old man presented with progressive hoarseness and dysphonia for the last 3 years. He had a history of bilateral carpal tunnel syndrome for which he had underwent surgery. Due to macroglossia, rhinomeglay and proteinuria, biopsy of the skin and oral mucosa was performed which was reported as amyloidosis. Laryngoscopy revealed severe inflammation with bilateral atrophy and stiffness of true vocal cords and hyperfunction of false vocal cord (Figure 1).

ECG findings showed left bundle branch block and atrial fibrillation with rapid ventricular response. Echocardiography revealed mild left ventricular hypertrophy, mild pericardial effusion and decreased tissue velocities. Serum protein electrophoresis was...
normal. CBC showed mild normocytic anemia. ESR was markedly elevated. Bone marrow aspiration and biopsy revealed more than 60% plasma cells compatible with multiple myeloma. During the serologic survey for hepatitis screening, he showed hepatitis B surface antigen positivity, so that he received Tenofovir because of heptitis B surface antigenemia before starting chemotherapy to prevent viral reactivation.

Amyloidosis of the larynx is a rare benign cause of hoarseness and dysphonia in the context of multiple myeloma. Its diagnosis may be delayed in patients with longstanding hoarseness. Treatment of choice is endoscopic Co2 laser excision. The prognosis of localized laryngeal amyloidosis is better than systemic AL amyloidosis.1

HBV infection may be associated with an increased risk of multiple myeloma.3,4 HBV reactivation was reported in patients with multiple myeloma after chemotherapy with Bortezomib,5-8 and in a case of primary amyloidosis after melphalan and dexamethasone combination therapy.9 We recommend screening for hepatitis B surface antigenemia in all patients with plasma cell dyscrasia including multiple myeloma and amyloidosis. Chemoprophylaxis for viral reactivation with antiviral agents such as lamivudine or tenofovir should be considered in seropositive patients before starting chemotherapy. In similar cases with plasma cell dyscrasia and HBs antigenemia, aggressive therapy is not required, but prophylaxis of viral reactivation with tenofovir before prescribing chemotherapy and further evaluation and follow-up to detect evolution into the systemic disease is suggested.

Conflict of Interest: None declared.

References